lördag den 27 april

Köpläge i amerikansk fondjätte

Pär Ståhl
Stockholmsbörsen
(), idag
-
-

Egetis Therapeutics
Egetis Therapeutics: New Data Validate the Long-term Efficacy of Emcitate (Redeye)

2021-10-25 10:40
Redeye comments on the newly published data from long-term treatment of lead candidate Emcitate (tiratricol) in MCT8 deficiency patients. We believe that the data demonstrate the importance of Emcitate and reaffirm our strong view of the treatment.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Egetis Therapeutics - I dag

{point.key}

Senaste nytt

Visa alla telegram

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex
Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor
Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor
Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror
Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -